Sanofi (SNY) 6-K Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2022

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

54, rue La Boétie, 75008 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒             Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes ☐                                No ☒

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________

In February 2022, Sanofi issued the press releases attached hereto as Exhibits 99.1, 99.2, 99.3 and 99.4 which are incorporated herein by reference.

Exhibit List

Exhibit No.	Description
Exhibit 99.1	Press release dated February 18, 2022: Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Exhibit 99.2	Press release dated February 22, 2022: Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors
Exhibit 99.3	Press release dated February 23, 2022: Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Exhibit 99.4	Press release dated February 23, 2022: Filing of the 2021 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

2

Exhibit Index

Exhibit No.	Description
Exhibit 99.1	Press release dated February 18, 2022: Update on ongoing Dupixent® (dupilumab) chronic spontaneous urticaria Phase 3 program
Exhibit 99.2	Press release dated February 22, 2022: Sanofi’s Board of Directors proposes the appointment of Carole Ferrand, Emile Voest and Antoine Yver as independent Directors
Exhibit 99.3	Press release dated February 23, 2022: Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine
Exhibit 99.4	Press release dated February  23, 2022: Filing of the 2021 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 24, 2022	SANOFI
	By	/s/ Alexandra Roger
		Name:   Alexandra Roger
		Title:     Head of Securities Law and               Capital Markets

4